New journal launched: Cancer Immunology Research
The American Association for Cancer Research has announced the electronic launch of its newest journal, Cancer Immunology Research, which will publish groundbreaking original articles on major advances in cancer immunology. A print preview issue is being distributed at the AACR Annual Meeting 2013, taking place April 6–10 at the Walter E. Washington Convention Center in Washington, D.C.
The journal will publish research articles reporting major advances in all areas of the discipline of cancer immunology, including basic investigations in host–tumor interactions, developmental therapeutics in model systems, early translational studies in patients and late-stage clinical trials. In addition to research articles, review articles and commentaries, the journal will include special features such as "Masters of Immunology," which will be primers by leading immunologists, and "Cancer Immunology at the Crossroads," which will be perspectives that highlight the relationship between immunology and other areas of cancer research and medicine.
"The AACR continuously strives to educate its members and the public about the most cutting-edge and relevant research to supports its goals of prevention and curing cancer," said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. "Cancer Immunology Research is an excellent addition to the AACR's robust group of cancer publications, and I am confident it will capture the most significant work in the field of cancer immunology, and inspire thinking that will accelerate the pace of breakthroughs."
Glenn Dranoff, M.D., professor of medicine at Dana-Farber Cancer Institute in Boston, Mass., is the founding editor-in-chief of Cancer Immunology Research. He is also the Harvard Medical School leader for the Dana-Farber/Harvard Cancer Center Program in Cancer Immunology. Dranoff has devoted much of his career and research efforts to understanding the mechanisms underlying the stimulation of tumor immunity and to applying these discoveries to the development of cancer vaccines.
"Cancer Immunology Research will play a leading role in educating the greater cancer research community regarding the principles and opportunities in cancer immunology," said Dranoff. "Recent clinical successes have validated the longstanding idea that therapeutic manipulation of the immune system may achieve meaningful antitumor effects.
"My vision is that by disseminating knowledge of cancer immunology, this journal will catalyze cross-disciplinary work that yields a deeper understanding of the host–tumor relationship, more potent cancer treatments and improved clinical outcomes," he added. "The launch of CIR has generated considerable enthusiasm in the cancer research community, and this is reflected in the outstanding didactic perspectives and original research articles to be published in the inaugural issue. This high level of scholarship and impact will be characteristic of CIR."
Specific topics of interest for publication include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies and clinical investigations.
Cancer Immunology Research is the eighth peer-reviewed scientific journal to be added to the AACR's publications portfolio. The AACR also publishes a magazine for cancer survivors, patients and their caregivers.
Provided by American Association for Cancer Research
